Stool Based Testing for Colorectal Cancer: an Overview of Available Evidence

被引：12

作者：

Rank K.M. ^{[1
]}

Shaukat A. ^{[1
]}

机构：

[1] Division of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, MN

来源：

Current Gastroenterology Reports | 2017年 / 19卷 / 8期

关键词：

Advanced adenoma; Colorectal cancer; Fit; gFOBT; hsFOBT; mtsDNA; Screening;

D O I：

10.1007/s11894-017-0579-4

中图分类号：

学科分类号：

摘要：

Purpose of Review: The goal of this review is to summarize stool-based testing for colorectal cancer (CRC). The key questions answered in this review were the advantages and limitations of each available stool-based test for CRC and to examine their comparative efficacy. Recent Findings: Guaiac-based fecal occult blood testing (gFOBT) is no longer a relevant test for CRC screening. fecal immunochemical testing (FIT) tests, especially quantitative assays, are clearly a reliable stool-based test. Multitarget DNA (mtsDNA) stool testing may represent a viable option as well, although cost and test characteristics are yet fully defined. Summary: FIT and mtsDNA represent the options for stool-based CRC screening. In larger screening centers, quantitative FIT assays represent an attractive option for stool-based testing. Qualitative FIT has applicability in smaller centers. Although a large validation trial showed promising results for mtsDNA, further head-to-head trials with FIT will help define the ultimate role of mtsDNA. Ultimately, however, the best test for CRC screening is the one performed stool-based CRC screening as an initial or alternative option can increase participation in CRC screening. © 2017, Springer Science+Business Media, LLC.

引用

共 37 条

[1]

Siegel R.L., Miller K.D., Jemal A., Cancer statistics, 2016, CA Cancer J Clin, 66, 1, pp. 7-30, (2016)

[2]

Vital signs: colorectal cancer screening test use—United States, 2012, MMWR, 62, 44, (2013)

[3]

DeBourcy A.C., Lichtenberger S., Felton S., Butterfield K.T., Ahnen D.J., Denberg T.D., Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening, J Gen Intern Med, 23, 2, pp. 169-174, (2008)

[4]

Inadomi J.M., Vijan S., Janz N.K., Fagerlin A., Thomas J.P., Lin Y.V., Munoz R., Somsouk M., El-Nachef N., Hayward R.A., Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies, Arch Intern Med, 172, 7, pp. 575-582, (2012)

[5]

Levin T.R., Colorectal cancer screening: 80% by 2018. Colonoscopists simply cannot do it alone, Gastrointest Endosc, 83, 3, pp. 552-554, (2016)

[6]

Mandel J.S., Church T.R., Ederer F., Bond J.H., Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood, J Natl Cancer Inst, 91, 5, pp. 434-437, (1999)

[7]

Shaukat A., Mongin S.J., Geisser M.S., Lederle F.A., Bond J.H., Mandel J.S., Church T.R., Long-term mortality after screening for colorectal cancer, N Engl J Med, 369, 12, pp. 1106-1114, (2013)

[8]

Hardcastle J.D., Armitage N.C., Chamberlain J., Amar S.S., James P.D., Balfour T.W., Fecal occult blood screening for colorectal cancer in the general population results of a controlled trial, Cancer, 58, 2, pp. 397-403, (1986)

[9]

DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer, (2016)

[10]

Faivre J., Dancourt V., Lejeune C., Tazi M.A., Lamour J., Gerard D., Dassonville F., Bonithon-Kopp C., Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study, Gastroenterology, 126, 7, pp. 1674-1680, (2004)

← 1 2 3 4 →